```markdown
<table>
<tr>
    <td colspan="20" align="left">Table 1 PLGG with KIAA1549:BRAF fusion: patient characteristics, response, and toxicity with trametinib</td>
</tr>
<tr>
    <td rowspan="2">Case (sex/years)</td>
    <td rowspan="2">Histology/diagnosis location</td>
    <td rowspan="2">First-line therapy</td>
    <td rowspan="2">Prior treatments (number)</td>
    <td rowspan="2">Time from diagnosis to T (years)</td>
    <td rowspan="2">Pre-treatment tumor size (cm<sup>3</sup>)</td>
    <td rowspan="2">Time on treatment (cycles/months)</td>
    <td rowspan="2">Best overall functional response</td>
    <td colspan="10">Side effects:</td>
</tr>
<tr>
    <td>Skin (grade I)</td>
    <td>AKI (grade I)</td>
    <td>Cleft hand (grade 1b)</td>
    <td>Adrenal (grade D) increased CK (grade I)</td>
    <td>Stable</td>
    <td>Stomatitis (grade 1a-1c)</td>
    <td>AKI (grade I)</td>
    <td>Fatigue, anorexia and weight loss</td>
    <td>Stable</td>
    <td>Mood changes (grade I)</td>
</tr>
<tr>
    <td>Case 1: 1.5 F</td>
    <td>PMA, hypothalamic-chiasmatic</td>
    <td>Biopsy CP-T I + CDP, VBL + BEV, CP-T, CDP + PR</td>
    <td>5</td>
    <td>3</td>
    <td>20</td>
    <td>PR</td>
    <td>Stable</td>
    <td>SD</td>
    <td>SD</td>
    <td>SD</td>
    <td>Stable</td>
    <td>SD</td>
    <td>SD</td>
    <td>Visual deterioration</td>
    <td>PD</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>SD</td>
</tr>
<tr>
    <td>Case 2: 0.5 M</td>
    <td>PMA, midline abdominal/ intracranial</td>
    <td>Biopsy CP-T I + CDP, VBL + BEV, CP-T, CDP + PR</td>
    <td>1</td>
    <td>1</td>
    <td>18</td>
    <td>5</td>
    <td>SD</td>
    <td>Resolved redundancy in hands</td>
    <td>PD</td>
    <td>PD</td>
    <td>Stable</td>
    <td>SD</td>
    <td>PD</td>
    <td>Visual deterioration</td>
    <td>PD</td>
    <td>PD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>SD</td>
</tr>
<tr>
    <td>Case 3: 0.9 F</td>
    <td>PMA, filamin-cell</td>
    <td>Biopsy CP-T I + CDP, VBL + BEV, PR</td>
    <td>3</td>
    <td>5</td>
    <td>Stores</td>
    <td>PD</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>PD</td>
    <td>SD</td>
    <td>SD</td>
    <td>PD</td>
    <td>Increased memory and attention concentration deterioration</td>
    <td>PD</td>
    <td>DSD</td>
    <td>SD</td>
    <td>PD</td>
    <td>PD</td>
</tr>
<tr>
    <td>Case 4: 1 M</td>
    <td>PMA, hypothalamic-chiasmatic</td>
    <td>Biopsy CP-T I + CDP, VBL + BEV, ECTO + BEV</td>
    <td>3</td>
    <td>5</td>
    <td>8</td>
    <td>Stable</td>
    <td>SD</td>
    <td>PD</td>
    <td>PD</td>
    <td>SD</td>
    <td>Stable</td>
    <td>SD</td>
    <td>PD</td>
    <td>Visual deterioration</td>
    <td>PD</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>SD</td>
</tr>
<tr>
    <td>Case 5: 4.4 F</td>
    <td>PMA, hypothalamic-chiasmatic</td>
    <td>Biopsy CP-T I + CDP, VBL + CDP, BEV</td>
    <td>1</td>
    <td>7.5</td>
    <td>14 (continues)</td>
    <td>3</td>
    <td>SD</td>
    <td>Dysmorphic syndrome improvement</td>
    <td>PD</td>
    <td>PD</td>
    <td>SD</td>
    <td>SD</td>
    <td>PD</td>
    <td>Visual improvement</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>SD</td>
    <td>SD</td>
</tr>
<tr>
    <td>Case 6: 5.8 F</td>
    <td>PMA, hypothalamic-chiasmatic</td>
    <td>Biopsy, VCRO, CCDA, BEV + BEV + CDP + PR</td>
    <td>1</td>
    <td>1.2</td>
    <td>14 (continues)</td>
    <td>2.9</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>PD</td>
    <td>SD</td>
    <td>SD</td>
    <td>PD</td>
    <td>Increased memory and resolution retention of problems in literacy</td>
    <td>PD</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>SD</td>
</tr>
<tr>
    <td>Case 7: 8.0 F</td>
    <td>PMA, inferior mandibular <br/>anorexia and arboreal <br/> and <br/> depression retinent</td>
    <td>Biopsy, VCRO, CDD, BEV + ECTO</td>
    <td>1</td>
    <td>1.2</td>
    <td>9.0</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>PD</td>
    <td>SD</td>
    <td>SD</td>
    <td>PD</td>
    <td>Mood changes improvement</td>
    <td>Visual deterioration</td>
    <td>PD</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>SD</td>
</tr>
<tr>
    <td>Case 8: 2.8 M</td>
    <td>PMA, hypothalamic-chiasmatic</td>
    <td>Biopsy, VCRO, CCDA, BEV + ECTO</td>
    <td>1</td>
    <td>2.9</td>
    <td>9.6</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>PD</td>
    <td>SD</td>
    <td>SD</td>
    <td>PD</td>
    <td>Stable</td>
    <td>Visual improvement</td>
    <td>PD</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>SD</td>
</tr>
<tr>
    <td>Case 9: 3.9 M</td>
    <td>PMA, hypothalamic-chiasmatic</td>
    <td>Biopsy, VCRO, CDD + BEV + EYCDP + BEV</td>
    <td>2</td>
    <td>2.0</td>
    <td>11.4</td>
    <td>Stable</td>
    <td>SD</td>
    <td>PD</td>
    <td>PD</td>
    <td>SD</td>
    <td>SD</td>
    <td>PD</td>
    <td>Descriptive syndrome improvement</td>
    <td>Visual improvement</td>
    <td>PD</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>SA</td>
</tr>
<tr>
    <td>Case 10: 0.4 M</td>
    <td>GG, Inferolaterally</td>
    <td>Biopsy</td>
    <td>1</td>
    <td>0.9</td>
    <td>12 (continues)</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>PD</td>
    <td>SD</td>
    <td>SD</td>
    <td>PD</td>
    <td>Reduced redundancy</td>
    <td>Visual improvement</td>
    <td>PD</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>SD</td>
</tr>
<tr>
    <td>Case 11: 1.1 F</td>
    <td>PMA, hypothalamic-chiasmatic</td>
    <td>Biopsy, VCRO, CCDA, BEV + EYCDP</td>
    <td>2</td>
    <td>1.3</td>
    <td>Yourdoit</td>
    <td>SD</td>
    <td>SD</td>
    <td>PD</td>
    <td>PD</td>
    <td>SD</td>
    <td>SD</td>
    <td>PD</td>
    <td>Increased memory and anorexia</td>
    <td>Visual deterioration</td>
    <td>PD</td>
    <td>SD</td>
    <td>Stable</td>
    <td>PD</td>
    <td>SD</td>
</tr>
</table>
```
